Abstract
Background: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. Methods: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.
Original language | English |
---|---|
Pages (from-to) | 1548-1550 |
Number of pages | 3 |
Journal | Journal of Crohn's & colitis |
Volume | 8 |
Issue number | 11 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- Biosimilar
- ECCO
- Inflammatory bowel disease
- Monoclonal
ASJC Scopus subject areas
- Gastroenterology
- Medicine(all)